Research Analysts Offer Predictions for OptiNose Q2 Earnings

OptiNose, Inc. (NASDAQ:OPTN - Free Report) - Analysts at HC Wainwright issued their Q2 2025 EPS estimates for OptiNose in a research note issued to investors on Monday, May 19th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.75) per share for the quarter. HC Wainwright currently has a "Neutral" rating and a $9.00 target price on the stock. The consensus estimate for OptiNose's current full-year earnings is ($3.22) per share. HC Wainwright also issued estimates for OptiNose's Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($1.14) EPS, FY2026 earnings at ($2.91) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($0.21) EPS and FY2029 earnings at $1.01 EPS.

A number of other equities research analysts have also recently commented on OPTN. Lake Street Capital cut shares of OptiNose from a "buy" rating to a "hold" rating and reduced their target price for the company from $17.00 to $9.00 in a research report on Thursday, March 20th. Piper Sandler reiterated a "neutral" rating and issued a $9.00 price objective (down previously from $15.00) on shares of OptiNose in a report on Friday, March 21st.

OptiNose Price Performance

Shares of OPTN remained flat at $9.60 during trading hours on Wednesday. The firm's 50 day moving average price is $9.21 and its 200-day moving average price is $7.39. OptiNose has a one year low of $4.82 and a one year high of $20.03. The firm has a market cap of $97.22 million, a PE ratio of -2.29 and a beta of -0.88.

OptiNose (NASDAQ:OPTN - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.27). The business had revenue of $18.51 million during the quarter, compared to analyst estimates of $17.70 million.

Insiders Place Their Bets

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total transaction of $33,729.04. Following the transaction, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. The trade was a 4.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 8,213 shares of company stock valued at $43,643. Insiders own 2.30% of the company's stock.

Institutional Investors Weigh In On OptiNose

A number of hedge funds have recently modified their holdings of the company. Acorn Capital Advisors LLC acquired a new position in OptiNose in the 4th quarter valued at about $2,824,000. PenderFund Capital Management Ltd. acquired a new position in OptiNose in the first quarter valued at approximately $172,000. Gabelli Funds LLC purchased a new position in OptiNose in the first quarter worth approximately $734,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in OptiNose during the first quarter worth $558,000. Finally, Groupe la Francaise purchased a new stake in OptiNose in the first quarter valued at $1,898,000. Hedge funds and other institutional investors own 85.60% of the company's stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.